Radiation oncology firm Accuray is highlighting a study conducted at 14 French centers that showed the clinical benefits of intensity-modulated radiation therapy (IMRT) delivered using its TomoTherapy system for patients with head and neck cancer.
For the study, published June 26 in the International Journal of Radiation Oncology, Biology, Physics, a team led by Dr. Jean-Emmanuel Bibault of Georges-Pompidou European Hospital in Paris included 166 patients. Of these, 74 were treated using the TomoTherapy system and 92 with radiation therapy firm Varian Medical Systems' volumetric modulated arc therapy with RapidArc.
Bibault's group found that at 18 months, the local control rate and cancer-specific survival rate were better in the TomoTherapy patient group than in the RapidArc group, Accuray said.
